Nanochip Technology in Monitoring Treatment Response and Detecting Relapse in Participants With Diffuse Large B-Cell Lymphoma

PRIMARY OBJECTIVES:

I. Determine whether ILN biochip can be used to detect molecular marker(s) to monitor
treatment response in patients with newly diagnosed diffuse large B-cell lymphoma (DLBCL).

II. Determine whether ILN biochip can promote early detection of disease relapse in patients
with DLBCL.

OUTLINE:

Participants' blood samples undergo ILN biochip testing at diagnosis, before and after every
course of chemotherapy, every 3 months for 2 years, and at relapse.

Inclusion Criteria:

- Histologically confirmed treatment naive DLBCL. Subtypes including high grade B-cell
lymphoma, not otherwise specified (NOS) and de-novo DLBCL including germinal center
B-cell type (GCB) and non-GCB subtypes.

- Intent to receive entire care (treatment and follow-up) at Ohio State University
(OSU).

- Receiving treatment with curative intent.

- Receiving planned 6 cycles of chemotherapy.

- Ability to consent.

Exclusion Criteria:

- Transformed lymphomas.

- DLBCL with leukemic presentation.

- Primary central nervous system (CNS) lymphoma.

- Participating in other clinical trial/ receiving experimental therapy.

- Patients with a "currently active" second malignancy that, in the opinion of the
principal investigator, will interfere with patient participation, or confound data
interpretation.

- Pregnancy (positive serum or urine pregnancy test) or breast feeding.